Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 258-753-8 | CAS number: 53770-52-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Read-across study therefore categorised as Klimisch 2.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 975
- Report date:
- 1975
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- Mixture containing zinc 3,5-bis(α-methylbenzyl)salicylate
- IUPAC Name:
- Mixture containing zinc 3,5-bis(α-methylbenzyl)salicylate
- Test material form:
- not specified
- Details on test material:
- The mixture contains 85% zinc 3,5-bis(α-methylbenzyl)salicylate and 15% PSMS.
Appearance: A whitish, crystalline powder, insoluble in water.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Wister rats were used, comprising of 10 per group.
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- not specified
- Details on oral exposure:
- The test substance was prepared for use by grinding to a fine powder in a mortar and making a suspension in 0.5% Tragacantha solution. The test substance was kept in solution using a magnetic stirrer.
- Doses:
- 0, 500, 1000, 1500, 2000 and 2500 mg/kg body weight.
- No. of animals per sex per dose:
- 10 per group
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 7 days
- Frequency of observations: No data
- Frequency of weighing: No data
- Necropsy of survivors performed: Autopsy of dead and surviving rats was performed.
Results and discussion
Effect levelsopen allclose all
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 2 500 mg/kg bw
- Based on:
- test mat.
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 1 720 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 246 - 2 374
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 2 125 mg/kg bw
- Based on:
- other: zinc 3,5-bis(α-methylbenzyl)salicylate
- Remarks on result:
- other: The test material contains 85% zinc 3,5-bis(α-methylbenzyl)salicylate
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 1 462 mg/kg bw
- Based on:
- other: zinc 3,5-bis(α-methylbenzyl)salicylate
- Remarks on result:
- other: The test material contains 85% zinc 3,5-bis(α-methylbenzyl)salicylate
- Mortality:
- Death rate showed a tendency to increase with the passage of time. There was no correlation between dosage level and number of deaths in males.
Male 2500 mg/kg bw: 50% mortality, male 2000 mg/kg bw: 20% mortality, male 1500 mg/kg bw: 40% mortality, male 1000 mg/kg bw: 10% mortality, male 500 mg/kg bw and 0 mg/kg bw: 0% mortality.
Female 2500 mg/kg bw: 60% mortality, female 2000 mg/kg bw: 70% mortality, female 1500 mg/kg bw: 40% mortality. - Clinical signs:
- other: No specific change in condition occurred following administration.
- Gross pathology:
- According to the autopsy of dead an surviving animals after 7 days, there were no significant changes, but chalasis of the intestinal tract and a tendency to hypertrophy of the liver were observed.
Applicant's summary and conclusion
- Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- In this study, the LD50 was found to be 2500 mg/kg in male Wistar rats and 1720 mg/kg in female Wistar rats for a mixture containing 85% zinc 3,5-bis(alpha-methylbenzyl)salicylate. Therefore, for zinc 3,5-bis(alpha-methylbenzyl)salicylate, the LD50 in male Wistar rats is 2125 mg/kg bw and the LD50 in female Wistar rats is 1462 mg/kg bw based on the test material containing 85% zinc 3,5-bis(alpha-methylbenzyl)salicylate.
- Executive summary:
An acute oral toxicity study with a mixture containing 85% zinc 3,5-bis(alpha-methylbenzyl)salicylate, was conducted in male and female Wistar rats.
The death rate showed a tendency to increase with time. There was no correlation between dosage level and number of deaths in males. According to the autopsy of dead and surviving animals after 7 days, there were no significant changes, but chalasis of the intestinal tract and a tendency to hypertrophy of the liver were observed. The LD50 was found to be 2500 mg/kg in male Wistar rats and 1720 mg/kg in female Wistar rats for a mixture containing 85% zinc 3,5-bis(alpha-methylbenzyl)salicylate. Therefore, for zinc 3,5-bis(alpha-methylbenzyl)salicylate, the LD50 in male Wistar rats is 2125 mg/kg bw and the LD50 in female Wistar rats is 1462 mg/kg bw based on the test material containing 85% zinc 3,5-bis(alpha-methylbenzyl)salicylate.
Zinc 3,5-bis(alpha-methylbenzyl)salicylate is therefore classified as Acute Oral Toxicity Category 4 in accordance with the CLP Regulation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
